Market Overview

Ascendiant Capital Raises PT on Photomedex After Better Than Expected Q4 Results

Related PHMD
20 Biggest Mid-Day Gainers For Wednesday
Mid-Day Market Update: Twilio Tumbles On Weak Guidance; Pieris Pharma Shares Climb

In a research report published Thursday, Ascendiant Capital analyst Keay Nakae raised the price target from $18 to $20 on Photomedex (NASDAQ: PHMD) and maintained a Strong Buy rating after better than expected Q4 results.

In the report Ascendiant said, "The Company ended the quarter with $62 MM in cash and equivalents compared to $55 MM at the end of Q3, even after spending $5.4 MM to repurchase 418K shares of its stock during the quarter. Management expects Q1 revenue to be at least $57 MM."

On Wednesday, Photomedex closed at $16.00.

Latest Ratings for PHMD

Nov 2014Canaccord GenuityMaintainsHold
Aug 2014Canaccord GenuityDowngradesBuyHold
May 2014AscendiantDowngradesBuyHold

View More Analyst Ratings for PHMD
View the Latest Analyst Ratings

Posted-In: Ascendiant CapitalAnalyst Color Price Target Analyst Ratings


Related Articles (PHMD)

View Comments and Join the Discussion!

Partner Center